Association between tea and coffee consumption and prevalence of metabolic syndrome in Poland – results from the WOBASZ II study (2013–2014)

Abstract

The study aimed to assess a relationship between tea and coffee consumption and metabolic syndrome (MetS). Cross-sectional study of a random sample of total Polish population was done (The WOBASZ II Study), and the present analysis included 5146 participants at age 20 years and above. Tea and coffee consumption was assessed by 24-h recall method. MetS was defined according to IDF/NHLBI/AHA criteria. After adjustment for covariates, coffee consumption was related to blood pressure and HDL cholesterol, and moderate drinkers had 17% lower odds of MetS compared with non-drinkers (OR = 0.83, 95%CI = 0.72–0.97). Tea consumption was related to some components but not to MetS in general. Inverse association between coffee consumption and MetS may reflect the content of the antioxidants that offer cardiovascular protection. However, weak relation of tea with components of MetS points toward the potential importance of composition of polyphenols and the types of tea consumed.

Keywords:

• Tea
• coffee
• metabolic syndrome
• waist circumference
• blood pressure
• dyslipidemia
• hyperglycaemia

Acknowledgements

The authors express special thanks to all the research team and collaborating persons from the field centres in 16 voivodships, and to all participants of the WOBASZ II study. The full list of WOBASZ II investigators can be found in Drygas et al. (2016).

The WOBASZ II project was funded from the financial resources at the disposal of the Minister of Health within the framework of the health programme entitled: National Program of Equalization the Accessibility to Cardiovascular Disease Prevention and Treatment for 2010–2012 POLKARD – goal: Analyses and epidemiology – “Monitoring of the epidemiological situation in Poland in the field of cardiovascular diseases”.

Disclosure statement

A. M., G. G., M. P., K. K., A. T., A. P. –W., W. D., and M. K. disclose no conflicts of interest. A. P. declared personal fees from AMGEN and Sanofi not related to the submitted work.